Focal segmental glomerulosclerosis explained

Focal segmental glomerulosclerosis
Synonyms:focal glomerular sclerosis, focal nodular glomerulosclerosis[1]

Focal segmental glomerulosclerosis (FSGS) is a histopathologic finding of scarring (sclerosis) of glomeruli and damage to renal podocytes.[2] [3] This process damages the filtration function of the kidney, resulting in protein presence in the urine due to protein loss. FSGS is a leading cause of excess protein loss—nephrotic syndrome—in children and adults in the US.[4] Signs and symptoms include proteinuria and edema.[5] Kidney failure is a common long-term complication of the disease.[6] FSGS can be classified as primary, secondary, or genetic, depending on whether a particular toxic or pathologic stressor or genetic predisposition can be identified as the cause.[7] [8] Diagnosis is established by renal biopsy,[9] and treatment consists of glucocorticoids and other immune-modulatory drugs.[10] Response to therapy is variable, with a significant portion of patients progressing to end-stage kidney failure. An American epidemiological study 20 years ago demonstrated that FSGS is estimated to occur in 7 persons per million, with cisgender male African-Americans at higher risk.[11] [12]

Signs and symptoms

The most common symptoms are a result of abnormal loss of protein from the glomerulus of the kidney, and include:

Common signs are also due to loss of blood proteins by the glomerulus of the kidney, including:

Pathophysiology

FSGS is primarily a disease of the renal glomerulus, the site of filtration of ions and solutes.[13] [14] Podocytes are specialized cells lining the Bowman's capsule that contribute to the filtration barrier, preventing molecules larger than 5 nm from being filtered.[15] FSGS involves damage to the renal podocytes such that larger molecules, most notably proteins, are filtered and lost through the kidney.[16] [17] Thus, many of the signs and symptoms of FSGS are related to protein loss.[18]

On histology, FSGS manifests as scarring (sclerosis) to segments of glomeruli; moreover, only a portion of glomeruli are affected.[19] [20] The focal and segmental nature of disease seen on histology help to distinguish FSGS from other types of glomerular sclerosis.

FSGS can be classified by the putative cause of damage to podocytes. Primary FSGS involves cases in which no cause is readily identifiable.[21] It is presumed that a set of unidentified circulating factors in the blood contribute to podocyte damage in these cases.[22]

Secondary FSGS is caused by an identifiable stress or toxin that injures podocytes. Many causes of secondary FSGS contribute to podocyte injury through hyperfiltration, which is a scenario of excess filtration by renal glomeruli.[23] Hyperfiltration can be caused by obesity, diabetes or loss of the contralateral kidney, among other causes.

Secondary FSGS can also be caused by toxins, including anabolic steroids and heroin.[24] [25]

A number of genes have been implicated in FSGS. These include: NPHS1, which encodes the protein nephrin that contributes to the filtration barrier;[26] NPHS2, which encodes the protein podocin found in podocytes;[27] and INF2, which encodes the actin-binding protein formin.[28]

The pathogenesis of HIV-associated FSGS is unclear, but may be due to the presence of the G1/G2 risk alleles of the APOL1 gene. There is some data to suggest that HIV can infect tubular epithelial cells and podocytes, but much remains to be known.[29]

Gain of function mutations in APOL1 have also been proposed to play a role in the pathogenesis of this disease.[30]

Diagnosis

Diagnosis of FSGS is made by renal biopsy that includes at least fifteen serial cuts with at least eight glomeruli.[31] [32] Histologic features include sclerosis (scarring) of a portion (average: 15%) of the glomerular space, with only a portion of glomeruli manifesting any sclerosis.[32]

Other tests helpful in the diagnosis include urine protein, urinalysis, serum albumin, and serum lipids. A clinical picture of proteinuria, low blood protein levels (albumin, antibodies), and high blood cholesterol would support a diagnosis of FSGS, although these do not help to distinguish between FSGS and other causes of proteinuria.

Classification

Five mutually exclusive variants of focal segmental glomerulosclerosis may be distinguished by the pathologic findings seen on renal biopsy:[33]

  1. Collapsing variant
  2. Glomerular tip lesion variant
  3. Cellular variant
  4. Perihilar variant
  5. Not otherwise specified (NOS) variant

Recognition of these variants may have prognostic value in individuals with primary focal segmental glomerulosclerosis. The collapsing variant is associated with higher rate of progression to end-stage renal disease, whereas the glomerular tip lesion variant has a low rate of progression to end-stage renal disease in most patients.[34] The cellular variant shows similar clinical presentation to collapsing and glomerular tip variant but has intermediate outcomes between the other two variants.

Treatment

First-line treatment for primary FSGS consists of anti-inflammatory drugs. Specifically, glucocorticoids are begun in patients manifesting with nephrotic-range proteinuria (>3.5 g/day).[35] [36] For patients who maintain nephrotic-range proteinuria despite glucocorticoids, or for patients who demonstrate glucocorticoid intolerance, calcineurin inhibitors (e.g., tacrolimus) are initiated. Successful treatment is defined as a drop in proteinuria to sub-nephrotic ranges.

The treatment of secondary FSGS involves addressing the particular toxic or stress agent.

Prognosis

The majority of untreated cases of FSGS will progress to end-stage kidney disease.[37] Important prognostic factors include the degree of proteinuria and initial response to therapy.

Patients with nephrotic-range (>3.5 g/day) proteinuria have over a 50% rate of progression to end-stage kidney disease at 10 years. Only 15% of patients with sub-nephrotic ranges of proteinuria progress to end-stage renal failure at 10 years.

Initial response to therapy also dictates long-term outcomes. Those defined as having a "complete response" typically manifest a proteinuria of <300 mg/day; those with a "partial response" manifest a sub-nephrotic range of proteinuria, <3.5 g/day.[38] Either complete or partial response is associated with 80% kidney survival at 10 years, compared with about 50% among non-responsive patients.

Epidemiology

FSGS accounts for 35% of all cases of nephrotic syndrome, making it one of the most common causes of nephrotic syndrome in the United States. FSGS accounts for 2% of all cases of kidney failure. African American patients have four times the likelihood of developing FSGS. Men are about two times as likely to develop FSGS compared to women.

Notable cases

See also

References

  1. "focal segmental glomerulosclerosis" at Dorland's Medical Dictionary.
  2. Rosenberg AZ, Kopp JB . Focal Segmental Glomerulosclerosis . Clin J Am Soc Nephrol . 12 . 3 . 502–517 . March 2017 . 28242845 . 5338705 . 10.2215/CJN.05960616 .
  3. D'Agati V . The many masks of focal segmental glomerulosclerosis . Kidney Int . 46 . 4 . 1223–41 . October 1994 . 7861720 . 10.1038/ki.1994.388 . free .
  4. Kitiyakara C, Eggers P, Kopp JB . Twenty-one-year trend in ESRD due to focal segmental glomerulosclerosis in the United States . Am J Kidney Dis . 44 . 5 . 815–25 . November 2004 . 10.1016/S0272-6386(04)01081-9 . 15492947 .
  5. Rydel JJ, Korbet SM, Borok RZ, Schwartz MM . Focal segmental glomerular sclerosis in adults: presentation, course, and response to treatment . Am J Kidney Dis . 25 . 4 . 534–42 . April 1995 . 7702047 . 10.1016/0272-6386(95)90120-5 .
  6. Korbet SM, Schwartz MM, Lewis EJ . Primary focal segmental glomerulosclerosis: clinical course and response to therapy . Am J Kidney Dis . 23 . 6 . 773–83 . June 1994 . 8203357 . 10.1016/s0272-6386(12)80128-4 .
  7. Web site: 2021-10-28 . Focal segmental glomerulosclerosis (FSGS) . 2023-11-14 . www.kidneyfund.org .
  8. Haas M, Meehan SM, Karrison TG, Spargo BH . Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976–1979 and 1995–1997 . Am J Kidney Dis . 30 . 5 . 621–31 . November 1997 . 9370176 . 10.1016/s0272-6386(97)90485-6 .
  9. Kiffel J, Rahimzada Y, Trachtman H . Focal segmental glomerulosclerosis and chronic kidney disease in pediatric patients . Adv Chronic Kidney Dis . 18 . 5 . 332–8 . September 2011 . 21896374 . 3709971 . 10.1053/j.ackd.2011.03.005 .
  10. Campbell KN, Tumlin JA . Protecting Podocytes: A Key Target for Therapy of Focal Segmental Glomerulosclerosis . Am J Nephrol . 47 . Suppl 1 . 14–29 . 2018 . 29852493 . 6589822 . 10.1159/000481634 .
  11. Tucker JK . Focal segmental glomerulosclerosis in African Americans . Am J Med Sci . 323 . 2 . 90–3 . February 2002 . 11863085 . 10.1097/00000441-200202000-00006 .
  12. Kitiyakara C, Kopp JB, Eggers P . Trends in the epidemiology of focal segmental glomerulosclerosis . Semin Nephrol . 23 . 2 . 172–82 . March 2003 . 12704577 . 10.1053/snep.2003.50025 .
  13. Wallace MA . Anatomy and physiology of the kidney . AORN J . 68 . 5 . 800, 803–16, 819–20; quiz 821–4 . November 1998 . 9829131 . 10.1016/s0001-2092(06)62377-6 .
  14. Pollak MR, Quaggin SE, Hoenig MP, Dworkin LD . The glomerulus: the sphere of influence . Clin J Am Soc Nephrol . 9 . 8 . 1461–9 . August 2014 . 24875196 . 4123398 . 10.2215/CJN.09400913 .
  15. Tojo A, Kinugasa S . Mechanisms of glomerular albumin filtration and tubular reabsorption . Int J Nephrol . 2012 . 481520 . 2012 . 22685655 . 3363986 . 10.1155/2012/481520 . free .
  16. Nagata M . Podocyte injury and its consequences . Kidney Int . 89 . 6 . 1221–30 . June 2016 . 27165817 . 10.1016/j.kint.2016.01.012 .
  17. Wang CS, Greenbaum LA . Nephrotic Syndrome . Pediatr Clin North Am . 66 . 1 . 73–85 . February 2019 . 30454752 . 10.1016/j.pcl.2018.08.006 .
  18. Web site: Focal Segmental Glomerulosclerosis (FSGS) . 2022-06-30 . Cleveland Clinic.
  19. Ichikawa I, Fogo A . Focal segmental glomerulosclerosis . Pediatr Nephrol . 10 . 3 . 374–91 . June 1996 . 8792409 . 10.1007/BF00866790 .
  20. Nagata M, Kobayashi N, Hara S . Focal segmental glomerulosclerosis; why does it occur segmentally? . Pflugers Arch . 469 . 7–8 . 983–8 . August 2017 . 28664408 . 10.1007/s00424-017-2023-x .
  21. De Vriese AS, Sethi S, Nath KA, Glassock RJ, Fervenza FC . Differentiating Primary, Genetic, and Secondary FSGS in Adults: A Clinicopathologic Approach . J Am Soc Nephrol . 29 . 3 . 759–774 . March 2018 . 29321142 . 5827609 . 10.1681/ASN.2017090958 .
  22. Rennke HG, Klein PS . Pathogenesis and significance of nonprimary focal and segmental glomerulosclerosis . Am J Kidney Dis . 13 . 6 . 443–56 . June 1989 . 2658558 . 10.1016/s0272-6386(89)80001-0 .
  23. Helal I, Fick-Brosnahan GM, Reed-Gitomer B, Schrier RW . Glomerular hyperfiltration: definitions, mechanisms and clinical implications . Nat Rev Nephrol . 8 . 5 . 293–300 . February 2012 . 22349487 . 10.1038/nrneph.2012.19 .
  24. Dubrow A, Mittman N, Ghali V, Flamenbaum W . The changing spectrum of heroin-associated nephropathy . Am J Kidney Dis . 5 . 1 . 36–41 . January 1985 . 3966467 . 10.1016/s0272-6386(85)80133-5 .
  25. Kasiske BL, Crosson JT . Renal disease in patients with massive obesity . Arch Intern Med . 146 . 6 . 1105–9 . June 1986 . 10.1001/archinte.1986.00360180095016 . 3718096 .
  26. Philippe A, Nevo F, Esquivel EL, Reklaityte D, Gribouval O, Tête MJ, Loirat C, Dantal J, Fischbach M, Pouteil-Noble C, Decramer S, Hoehne M, Benzing T, Charbit M, Niaudet P, Antignac C . Nephrin mutations can cause childhood-onset steroid-resistant nephrotic syndrome . J Am Soc Nephrol . 19 . 10 . 1871–8 . October 2008 . 18614772 . 2551572 . 10.1681/ASN.2008010059 .
  27. Boute N, Gribouval O, Roselli S, Benessy F, Lee H, Fuchshuber A, Dahan K, Gubler MC, Niaudet P, Antignac C . NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome . Nat Genet . 24 . 4 . 349–54 . April 2000 . 10742096 . 10.1038/74166 .
  28. Brown EJ, Schlöndorff JS, Becker DJ, Tsukaguchi H, Tonna SJ, Uscinski AL, Higgs HN, Henderson JM, Pollak MR . Mutations in the formin gene INF2 cause focal segmental glomerulosclerosis . Nat Genet . 42 . 1 . 72–6 . January 2010 . 20023659 . 2980844 . 10.1038/ng.505 .
  29. Chang, Anthony, Robbins & Cotran Pathologic Basis of Disease, Chapter 20, 895–952
  30. Kopp JB, Nelson GW, Sampath K, Johnson RC, Genovese G, An P, Friedman D, Briggs W, Dart R, Korbet S, Mokrzycki MH, Kimmel PL, Limou S, Ahuja TS, Berns JS, Fryc J, Simon EE, Smith MC, Trachtman H, Michel DM, Schelling JR, Vlahov D, Pollak M, Winkler CA . APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy . J Am Soc Nephrol . 22 . 11 . 2129–37 . November 2011 . 21997394 . 3231787 . 10.1681/ASN.2011040388 .
  31. Fuiano G, Comi N, Magri P, Sepe V, Balletta MM, Esposito C, Uccello F, Dal Canton A, Conte G . Serial morphometric analysis of sclerotic lesions in primary "focal" segmental glomerulosclerosis . J Am Soc Nephrol . 7 . 1 . 49–55 . January 1996 . 8808109 . 10.1681/ASN.V7149 .
  32. Schwartz MM, Korbet SM . Primary focal segmental glomerulosclerosis: pathology, histological variants, and pathogenesis . Am J Kidney Dis . 22 . 6 . 874–83 . December 1993 . 8250036 . 10.1016/s0272-6386(12)70349-9 .
  33. Thomas DB, Franceschini N, Hogan SL, Ten Holder S, Jennette CE, Falk RJ, Jennette JC . Clinical and pathologic characteristics of focal segmental glomerulosclerosis pathologic variants . Kidney Int . 69 . 5 . 920–6 . March 2006 . 16518352 . 10.1038/sj.ki.5000160 . free.
  34. Agnes Fogo . Fogo AB . Causes and pathogenesis of focal segmental glomerulosclerosis . Nat Rev Nephrol . 11 . 2 . 76–87 . February 2015 . 25447132 . 4772430 . 10.1038/nrneph.2014.216 .
  35. Chen YM, Liapis H . Focal segmental glomerulosclerosis: molecular genetics and targeted therapies . BMC Nephrol . 16 . 101 . July 2015 . 26156092 . 4496884 . 10.1186/s12882-015-0090-9 . free .
  36. Raina R, Wang J, Sharma A, Chakraborty R . Extracorporeal Therapies in the Treatment of Focal Segmental Glomerulosclerosis . Blood Purif . 49 . 5 . 513–523 . 2020 . 32074606 . 10.1159/000506277 .
  37. Deegens JK, Assmann KJ, Steenbergen EJ, Hilbrands LB, Gerlag PG, Jansen JL, Wetzels JF . Idiopathic focal segmental glomerulosclerosis: a favourable prognosis in untreated patients? . Neth J Med . 63 . 10 . 393–8 . November 2005 . 16301760 .
  38. Troyanov S, Wall CA, Miller JA, Scholey JW, Cattran DC . Focal and segmental glomerulosclerosis: definition and relevance of a partial remission . J Am Soc Nephrol . 16 . 4 . 1061–8 . April 2005 . 15716334 . 10.1681/ASN.2004070593 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Focal segmental glomerulosclerosis".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.